Zealand Pharma A/S (OTCMKTS:ZLDPF) Issues Quarterly Earnings Results

Key Points

• Zealand Pharma A/S reported a quarterly earnings per share (EPS) of $16.06, with a negative return on equity of 13.40% and a staggering negative net margin of 2,127.09%.
• The company's share price increased by 1.0% to $54.03, with a market cap of $3.84 billion and current and quick ratios of 25.10 and 25.07, respectively.
• Several analysts, including BNP Paribas and Barclays, have upgraded Zealand Pharma A/S to a "strong-buy" rating, reflecting positive investor sentiment towards the stock.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) announced its quarterly earnings results on Thursday. The company reported $16.06 earnings per share (EPS) for the quarter, Zacks reports. Zealand Pharma A/S had a negative return on equity of 13.40% and a negative net margin of 2,127.09%.

Zealand Pharma A/S Trading Up 1.0%

Shares of Zealand Pharma A/S stock traded up $0.53 on Thursday, hitting $54.03. 180 shares of the company traded hands, compared to its average volume of 869. The stock's 50 day moving average price is $58.65 and its 200-day moving average price is $71.79. The company has a current ratio of 25.10, a quick ratio of 25.07 and a debt-to-equity ratio of 0.03. Zealand Pharma A/S has a 52 week low of $49.98 and a 52 week high of $141.74. The company has a market cap of $3.84 billion, a PE ratio of -21.70 and a beta of 0.71.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, July 1st. Barclays raised Zealand Pharma A/S to a "strong-buy" rating in a report on Monday, July 7th. Finally, Wells Fargo & Company raised Zealand Pharma A/S to a "strong-buy" rating in a research note on Thursday, July 24th. One analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Strong Buy".

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.